Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2P-TIMI 50 trial

: Scicira BM, Bonaca MP, Braunwald E, De Ferrari GM, Isaza D, Lewis BS, Mehrhof F, Merlini PA, Murphy SA, Sabatine MS, Tendera M, Van de Werf F, Wilcox R, Morrow DA, the TRA 2P-TIMI 50 Steering Committee and Investigators, Airaksinen J

: 2012

: Lancet

: 380

: 9850

: 1317

: 1324

: 8

: 0140-6736

DOI: https://doi.org/10.1016/S0140-6736(12)61269-0(external)